{
}
Ionis Pharmaceuticals presented its neurology pipeline at UBS Virtual CNS Day, focusing on rare neurological diseases such as Alexander disease, Angelman syndrome, and Alzheimer's disease. The company reported an 84% growth in WAYNEUWA sales and is optimistic about upcoming clinical trial results, including a Phase 3 trial for Angelman syndrome and data for Alexander disease expected later this year. Future plans include collaborations for faster diagnoses and expanding treatment options for young patients.
Alzheimer’s drug development is gaining investor attention, with Biogen's Leqembi and Eli Lilly's Kisunla leading the market despite their limitations in reversing the disease. Novo Nordisk is exploring semaglutide's potential benefits for early Alzheimer’s patients, while Roche and UCB are assessing new treatments amid mixed trial results. The landscape is dynamic, with significant opportunities for firms that can deliver effective therapies.
Novartis' intrathecal formulation of onasemnogene abeparvovec (OAV101 IT) has shown promising results in a Phase III STEER study for pediatric patients aged 2-17 with type II spinal muscular atrophy (SMA), potentially expanding the eligible patient population for gene therapy. The therapy demonstrated a favorable safety profile, with common adverse events including upper respiratory infections and pyrexia. If approved, OAV101 IT could significantly improve treatment access for patients in regions lacking newborn screening initiatives.
Novartis' intrathecal formulation of onasemnogene abeparvovec (OAV101 IT) has met primary endpoints in a Phase III STEER study for pediatric patients aged 2-17 with type II spinal muscular atrophy (SMA), potentially expanding the treatment population. Projected sales for both IT and intravenous formulations are expected to rise from $660.6 million in 2023 to $763.8 million by 2033, driven by increased awareness and newborn screening initiatives. If approved, OAV101 IT could significantly improve outcomes for patients in regions lacking early diagnosis or screening.
Novartis' intrathecal formulation of onasemnogene abeparvovec (OAV101 IT) has shown positive results in a Phase III study for treating type II spinal muscular atrophy (SMA) in children aged 2-17, potentially expanding the eligible patient population for gene therapy. The treatment demonstrated clinical benefits and a favorable safety profile, with common adverse events being manageable. If approved, OAV101 IT could significantly benefit patients in regions without newborn screening initiatives or those diagnosed later, while projected sales for both OAV101 formulations are expected to rise significantly by 2033.
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
Roche and Prothena's Parkinson's antibody treatment, prasinezumab, failed to meet its primary endpoint in the phase 2b PADOVA study, although it showed a 16% delay in motor progression compared to placebo. The drug was well tolerated, and Roche plans to further evaluate the data and collaborate with health authorities on next steps. Parkinson's disease remains difficult to treat, with many therapies struggling to progress through clinical trials.
Roche's phase 2b trial of prasinezumab, an anti-alpha-synuclein antibody partnered with Prothena, failed to meet its primary endpoint for treating early-stage Parkinson's disease, with a p value of 0.0657. However, Roche highlighted potential clinical efficacy in a subgroup receiving levodopa, showing a nominal p value of 0.0431. Despite the setbacks in alpha-synuclein targeting therapies, Roche plans to continue tracking patients and evaluate future steps after discussions with regulators.
UCB's investigational small molecule minzasolmin, developed in partnership with Novartis, has failed to meet primary and secondary endpoints in a phase 2a trial for early-stage Parkinson's disease, leading to the termination of its extension phase. The study, which involved 496 patients, showed comparable treatment-emergent adverse events across groups, with no new safety risks identified. UCB continues to explore alpha-synuclein pathology with other candidates, including UCB7583 and glovadalen, the latter of which is in a phase 2 trial with results expected in March 2025.
The global Precision Medicine market, valued at $89.9 billion in 2023, is projected to reach $161.1 billion by 2030, growing at a CAGR of 8.7%. Key drivers include advancements in genomic sequencing, rising chronic disease prevalence, and increased investment in targeted therapies, particularly in oncology. The integration of AI and machine learning is further enhancing personalized treatment approaches, paving the way for more effective healthcare solutions.
BIOGEN
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Ionis Pharmaceuticals Advances Neurology Pipeline with Promising Clinical Developments
13:10 18.03.2025
alzheimer's drug developments signal potential investment opportunities in 2025
Euro
United States Dollar
Novo Nordisk A/S
Eisai Co., Ltd.
Eli Lilly and Co
BioArctic AB
Hoffmann-La Roche AG
UCB SA
AXA Investment Managers SA
BIOGEN
BEL
JPN
USA
SWE
Gregoire Biollaz
Colin White
Sachin Jain
Jean Rivera Irizarry
Chris Eccleshall
Emily Field
Stacy Kubicek
Show more
18:36 10.01.2025
novartis gene therapy shows promise for expanding treatment options in sma
12:43 07.01.2025
novartis gene therapy shows promise for expanding treatment options in sma
United States Dollar
Novartis AG
Hoffmann-La Roche AG
BIOGEN
FRA
ESP
DEU
ITA
JPN
GBR
USA
Christie Wong
Show more
06:24 07.01.2025
novartis gene therapy shows promise for expanding treatment options in sma
11:45 03.01.2025
global uveitis treatment market poised for significant growth by 2032
Pfizer Inc.
Bayer AG
Novartis AG
Regeneron Pharmaceuticals, Inc.
Merck & Co., Inc.
CIPLA LTD
Lupin Limited
Hoffmann-La Roche AG
Bausch Health Companies Inc.
BIOGEN
ABBVIE
Alimera Sciences Inc.
SAU
ISR
FRA
RUS
DEU
TWN
ARG
ARE
AUT
TUR
SGP
NZL
CHL
USA
BRA
CAN
ITA
JPN
IDN
GBR
ESP
IND
MYS
COL
AUS
THA
EGY
VNM
KOR
PHL
CHN
ZAF
MEX
Nidhi Bhavsar
Show more
20:41 19.12.2024
roche and prothena's parkinsons antibody treatment fails in phase 2 trial
United States Dollar
UCB SA
Hoffmann-La Roche AG
Prothena Corp PLC
Novartis AG
BIOGEN
IRL
Levi Garraway
Show more
15:39 19.12.2024
Roche reports phase 2b failure for Parkinson's treatment but sees potential benefits
10:31 19.12.2024
ucb's parkinson's drug minzasolmin fails in phase 2 trial
United States Dollar
Prothena Corp PLC
Hoffmann-La Roche AG
UCB SA
BIOGEN
Novartis AG
CHE
BEL
USA
Show more
21:19 16.12.2024
global precision medicine market projected to reach 161 billion by 2030
SIEMENS HEALTHINEERS
Medtronic plc
Quest Diagnostics Incorporated
Genesis Healthcare, Inc.
Abbott Laboratories
Myriad Genetics Inc
BIOGEN
F. Hoffmann-La Roche Ltd.
Illumina, Inc.
DEU
CAN
CHN
JPN
USA
Show more
14:51 13.12.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Finance Mergers & Acquisitions
Retail and Consumer Goods
Banking Regulations
Startups & Entrepreneurship
Industry Mergers & Acquisitions
CEO Changes
Market Analysis and Predictions
Government Economic Policies
Government Policies
Inflation and Monetary Impact
Central Bank Actions
GDP Growth & Recession Forecasts
Commodities
Consumer Protection Regulations
Domestic Politics
Countries:
Companies:
Barclays PLC
JPMorgan Chase & Co.
Apple Inc.
Tesla, Inc.
Berkshire Hathaway Inc.
Banco Santander, S.A.
The Goldman Sachs Group, Inc.
Microsoft Corporation
Commerzbank AG
Amazon.com, Inc.
Lloyds Banking Group plc
NVIDIA Corporation
Morgan Stanley
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
SpaceXCoin USD
Deutsche Bank Money Market PP
Royal Bank of Canada
UBS Group AG
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Chinese Yuan
South Korean Won
New Taiwan Dollar
Canadian Dollar
United Arab Emirates Dirham
Vietnamese Đồng
Danish Krone
Indonesian Rupiah
Russian Ruble
Singapore Dollar
Chilean Peso
Egyptian Pound
Cambodian Riel
People: